Your browser doesn't support javascript.
loading
Re-education of Tumor-Associated Macrophages by CXCR2 Blockade Drives Senescence and Tumor Inhibition in Advanced Prostate Cancer.
Di Mitri, Diletta; Mirenda, Michela; Vasilevska, Jelena; Calcinotto, Arianna; Delaleu, Nicolas; Revandkar, Ajinkya; Gil, Veronica; Boysen, Gunther; Losa, Marco; Mosole, Simone; Pasquini, Emiliano; D'Antuono, Rocco; Masetti, Michela; Zagato, Elena; Chiorino, Giovanna; Ostano, Paola; Rinaldi, Andrea; Gnetti, Letizia; Graupera, Mariona; Martins Figueiredo Fonseca, Ana Raquel; Pereira Mestre, Ricardo; Waugh, David; Barry, Simon; De Bono, Johann; Alimonti, Andrea.
Afiliación
  • Di Mitri D; Istituto Clinico Humanitas, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Via A. Manzoni 113, 20089 Rozzano, Milan, Italy.
  • Mirenda M; Institute of Oncology Research (IOR), 6500 Bellinzona, Switzerland.
  • Vasilevska J; Institute of Oncology Research (IOR), 6500 Bellinzona, Switzerland.
  • Calcinotto A; Institute of Oncology Research (IOR), 6500 Bellinzona, Switzerland.
  • Delaleu N; Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, 5021 Bergen, Norway; Swiss Institute of Bioinformatics, Lausanne, Switzerland; 2C SysBioMed, 6646 Contra, Switzerland.
  • Revandkar A; Institute of Oncology Research (IOR), 6500 Bellinzona, Switzerland.
  • Gil V; The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK.
  • Boysen G; The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK.
  • Losa M; Institute of Oncology Research (IOR), 6500 Bellinzona, Switzerland.
  • Mosole S; Institute of Oncology Research (IOR), 6500 Bellinzona, Switzerland.
  • Pasquini E; Institute of Oncology Research (IOR), 6500 Bellinzona, Switzerland.
  • D'Antuono R; Institute for Research in Biomedicine (IRB), 6500 Bellinzona, Switzerland.
  • Masetti M; Istituto Clinico Humanitas, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Via A. Manzoni 113, 20089 Rozzano, Milan, Italy.
  • Zagato E; Institute of Oncology Research (IOR), 6500 Bellinzona, Switzerland.
  • Chiorino G; Cancer Genomics Lab, Fondazione Edo ed Elvo Tempia, Via Malta, 3, 13900 Biella, Italy.
  • Ostano P; Cancer Genomics Lab, Fondazione Edo ed Elvo Tempia, Via Malta, 3, 13900 Biella, Italy.
  • Rinaldi A; Institute of Oncology Research (IOR), 6500 Bellinzona, Switzerland.
  • Gnetti L; Pathology Unit, University Hospital of Parma, 43126 Parma, Italy.
  • Graupera M; Vascular Signalling Laboratory, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Barcelona, Spain; Program Against Cancer Therapeutic Resistance (ProCURE), Barcelona, Spain; CIBERONC, Madrid, Spain.
  • Martins Figueiredo Fonseca AR; Vascular Signalling Laboratory, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Barcelona, Spain; Program Against Cancer Therapeutic Resistance (ProCURE), Barcelona, Spain; CIBERONC, Madrid, Spain.
  • Pereira Mestre R; Medical Oncology, Oncology Institute of Southern Switzerland, 6500 Bellinzona, Switzerland.
  • Waugh D; Movember Centre of Excellence, Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, UK.
  • Barry S; IMED Oncology AstraZeneca, Li KaShing Centre, Cambridge, UK.
  • De Bono J; The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK.
  • Alimonti A; Institute of Oncology Research (IOR), 6500 Bellinzona, Switzerland; Faculty of Medicine, Università della Svizzera Italiana, 1011 Lugano, Switzerland; Department of Medicine, University of Padua, 35131 Padua, Italy; Medical Oncology, Oncology Institute of Southern Switzerland, 6500 Bellinzona, Switz
Cell Rep ; 28(8): 2156-2168.e5, 2019 08 20.
Article en En | MEDLINE | ID: mdl-31433989
ABSTRACT
Tumor-associated macrophages (TAMs) represent a major component of the tumor microenvironment supporting tumorigenesis. TAMs re-education has been proposed as a strategy to promote tumor inhibition. However, whether this approach may work in prostate cancer is unknown. Here we find that Pten-null prostate tumors are strongly infiltrated by TAMs expressing C-X-C chemokine receptor type 2 (CXCR2), and activation of this receptor through CXCL2 polarizes macrophages toward an anti-inflammatory phenotype. Notably, pharmacological blockade of CXCR2 receptor by a selective antagonist promoted the re-education of TAMs toward a pro-inflammatory phenotype. Strikingly, CXCR2 knockout monocytes infused in Ptenpc-/-; Trp53pc-/- mice differentiated in tumor necrosis factor alpha (TNF-α)-releasing pro-inflammatory macrophages, leading to senescence and tumor inhibition. Mechanistically, PTEN-deficient tumor cells are vulnerable to TNF-α-induced senescence, because of an increase of TNFR1. Our results identify TAMs as targets in prostate cancer and describe a therapeutic strategy based on CXCR2 blockade to harness anti-tumorigenic potential of macrophages against this disease.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Senescencia Celular / Receptores de Interleucina-8B / Macrófagos Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Cell Rep Año: 2019 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Senescencia Celular / Receptores de Interleucina-8B / Macrófagos Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Cell Rep Año: 2019 Tipo del documento: Article